Key result
ACE gene I/D polymorphism shows no association with breast cancer risk.
Why the study?
Previous case-control studies on the relation between ACE gene I/D polymorphism and breast cancer did not reach the same conclusion.
Is the ACE gene I/D polymorphism associated with breast cancer risk?
Meta-Analysis (n=10,405)
Is the ACE gene I/D polymorphism associated with breast cancer risk?
Odds Ratio: 1.28 (95% CI 0.9–1.81)
p-value: p=0.16
This meta-analysis demonstrates that the ACE gene I/D polymorphism is not associated with breast cancer risk.
No association with ACE I/D polymorphism; leaves open other genetic or environmental factors for targeted research.
OBJECTIVE: Previous case-control studies on the relation between angiotensin-converting enzyme (ACE) gene insertion/deletion (I/D) polymorphism and breast cancer did not reach the same conclusion. In the present study, we aimed to further evaluate the relationship between the ACE gene I/D polymorphism and breast cancer. METHODS: We selected 13 case-control studies related to ACE gene I/D polymorphism and breast cancer by searching PubMed, EMBase, Chinese Biomedical Literature Database, Chinese CNKI, and Wanfang database. To test the heterogeneity between each study, we utilized the Q-test and I(2) test. To merge the odds ratio (OR) and 95% confidence interval (CI), we utilized the random effects model during the analyses. RESULTS: The present study included 1997 patients with breast cancer and 8404 cancer-free control subjects. By meta-analysis, we did not find any association of ACE gene I/D polymorphism with breast cancer in different model (DD vs (ID+II): OR=1.28, 95% CI (0.90-1.81), p=0.16; II vs (ID+DD): OR=0.99, 95% CI (0.81-1.21), p=0.93; D allele vs I allele: OR=1.15, 95% CI (0.94-1.41), p=0.18). CONCLUSION: We concluded that ACE gene I/D polymorphism was not associated with breast cancer.
No takes yet. Share an insight, caveat, or question.
Li et al. (2014) conducted a meta-analysis in Breast cancer (n=10,405). ACE gene I/D polymorphism (DD genotype) vs. ID+II genotypes was evaluated on Breast cancer (OR 1.28, 95% CI 0.90-1.81, p=0.16). The ACE gene I/D polymorphism was not associated with breast cancer in the DD vs (ID+II) model (OR 1.28; 95% CI 0.90-1.81; p=0.16) or other genetic models.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: